155 related articles for article (PubMed ID: 15205948)
21. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
McDermott U; Longley DB; Galligan L; Allen W; Wilson T; Johnston PG
Cancer Res; 2005 Oct; 65(19):8951-60. PubMed ID: 16204068
[TBL] [Abstract][Full Text] [Related]
22. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Tanaka K; Inoue Y; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M
J Exp Clin Cancer Res; 2007 Jun; 26(2):241-51. PubMed ID: 17725105
[TBL] [Abstract][Full Text] [Related]
23. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
24. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M
J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin: a new therapeutic option in colorectal cancer.
Cvitkovic E; Bekradda M
Semin Oncol; 1999 Dec; 26(6):647-62. PubMed ID: 10606258
[TBL] [Abstract][Full Text] [Related]
26. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Yasui H; Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2009 May; 39(5):315-20. PubMed ID: 19403734
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
28. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
[TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
31. [A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Sagawa T; Tsuji Y; Takayanagi N; Hirayama Y; Sakamaki S; Chiba H; Iyama S; Oku T; Sato Y; Takahashi M; Takayama T; Niitsu Y
Gan To Kagaku Ryoho; 2003 Apr; 30(4):537-43. PubMed ID: 12722689
[TBL] [Abstract][Full Text] [Related]
32. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Tokunaga Y; Sasaki H; Matsueda S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
[TBL] [Abstract][Full Text] [Related]
33. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
[TBL] [Abstract][Full Text] [Related]
34. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
Gu WJ; Liu HL
Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
[TBL] [Abstract][Full Text] [Related]
35. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
[TBL] [Abstract][Full Text] [Related]
36. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
[TBL] [Abstract][Full Text] [Related]
37. Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Popov IP; Jelic SB; Matijasevic MM; Grbic B; Babic DR
J Exp Clin Cancer Res; 2004 Sep; 23(3):395-401. PubMed ID: 15595627
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 2000; 45(3):252-8. PubMed ID: 10663644
[TBL] [Abstract][Full Text] [Related]
39. Combined modulation by leucovorin and alpha-2a interferon of fluoropyrimidine mediated growth inhibition.
Sinnige HA; Timmer-Bosscha H; Peters GF; De Vries EG; Mulder NH
Anticancer Res; 1993; 13(5A):1335-40. PubMed ID: 8239504
[TBL] [Abstract][Full Text] [Related]
40. Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin.
Milczarek M; Rosinska S; Psurski M; Maciejewska M; Kutner A; Wietrzyk J
Anticancer Res; 2013 Feb; 33(2):433-44. PubMed ID: 23393334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
